Cordlife Group

Lower births and a cut back in discretionary spending are likely factors to be a drag on Cordlife’s organic revenue.

Cordlife extends reach and expands breadth.

SCCM has maintained its "buy" call and raised its target price to 52 cents on the stock.

SINGAPORE (Nov 12): Cordlife Group reported earnings of $3.7 million for the 15 months ended Sept, reversing a loss of $2 million for the same period a year earlier.

SINGAPORE (May 25): As parents in Singapore grow wealthier, more of them are signing up for what has been hailed as potential “lifesaver” – cord blood banking.

SINGAPORE (May 11): Cordlife Group reported its fourth straight quarterly earnings as higher revenue from key markets and contributions from a newly-acquired subsidiary lifted profit from operations.

SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.

SINGAPORE (Apr 9): Cordlife Group is launching US-based genetic testing service PlumCare DNA Advisor in Singaoore.

SINGAPORE (Feb 26): Consumer healthcare company Cordlife Group is partnering US-based PlumCare to offer a genetic testing service to help families in Asia identify gene variants associated with increased risk of developing inherited conditions such as bre

SINGAPORE (Jan 3): Cordlife Group is fully acquiring a private cord blood bank in Hong Kong, HealthBaby Hong Kong, for US$7 million in cash ($9.3 million) after adjusting for US$2.5 million in the company’s cash and bank loans that will remain in place.